I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Wet Macular Degeneration: Causes, Symptoms, and Treatment
Understanding Wet AMD
Wet AMD is not simply a worsening of dry AMD. It is a distinct process with its own behavior, risks, and treatment needs. Understanding how it develops helps explain why prompt evaluation and consistent treatment matter so much.
The macula is the part of the retina responsible for reading, driving, recognizing faces, and seeing fine details. In wet AMD, abnormal blood vessels grow beneath the retina in a process called choroidal neovascularization. These vessels are fragile and tend to leak blood, fluid, and fatty deposits into the retinal tissue. Over time, this leakage damages the macula and can lead to scarring that permanently destroys central vision.
Wet AMD is classified as an advanced form of AMD. While it represents a smaller share of all AMD cases than the dry form, wet AMD is responsible for the majority of AMD-related severe central vision loss.
Dry AMD is the more common form of the disease. It develops when small yellow deposits called drusen accumulate beneath the retina, and the light-sensitive cells in the macula gradually deteriorate over years. Progression is usually slow.
Wet AMD behaves very differently. It can cause serious vision loss in weeks to months rather than years. Any stage of dry AMD can convert to wet AMD, sometimes without obvious warning signs at first. This is why regular monitoring by a retina specialist is so important for anyone living with dry AMD, even when vision currently feels stable.
As the eye ages, changes in the layers beneath the retina can reduce the flow of nutrients and oxygen to retinal cells. In response, the retina begins producing excessive amounts of a protein called vascular endothelial growth factor, or VEGF. High VEGF levels signal the body to grow new blood vessels from the choroid, a dense network of blood vessels beneath the retina.
These new vessels are structurally weak and prone to leaking. The blood and fluid they release disrupt the delicate layers of the retina and cause rapid death of photoreceptor cells, the light-sensing cells that make vision possible. Over time, this process leads to scarring and lasting damage to central vision.
Who Is at Risk for Wet AMD
Several factors can increase a person's likelihood of developing wet AMD. Some are outside of your control, but others may be influenced through lifestyle choices and ongoing health management.
Age is the single strongest risk factor for wet AMD. The condition primarily affects people over the age of 50, and risk increases significantly with each passing decade. Hundreds of thousands of new wet AMD cases are diagnosed each year in North America, and the condition becomes increasingly common as populations age.
Genetics play a meaningful role in AMD risk. People with a close family member who has AMD face a substantially higher likelihood of developing the condition themselves. Research suggests that genetic factors may account for roughly half of all AMD cases. Having dry AMD in one or both eyes is also a significant risk factor for eventual conversion to wet AMD.
Several modifiable health and lifestyle factors are linked to wet AMD. Addressing these where possible may help reduce overall risk or slow disease progression.
- Smoking is one of the most significant lifestyle risks, increasing AMD likelihood by two to three times
- Cardiovascular disease and high blood pressure are associated with increased retinal disease risk
- High cholesterol levels have been linked to AMD progression
- Obesity may increase the risk of AMD progressing to more advanced stages
- Extended exposure to ultraviolet light without protective eyewear may also be a contributing factor
Quitting smoking, managing blood pressure and cholesterol, staying at a healthy weight, and wearing UV-protective sunglasses are all steps that may support long-term eye health.
Certain demographic characteristics are associated with higher wet AMD risk. People of Caucasian descent have a higher prevalence of AMD compared to other racial groups. Women are affected more frequently than men overall. People with lighter-colored eyes may face a modestly higher risk due to less natural pigment protection in the retina.
Signs and Symptoms of Wet AMD
Wet AMD often develops more suddenly than other eye conditions. Recognizing the early signs and knowing when to seek urgent care are essential steps in protecting your vision.
One of the most characteristic early symptoms of wet AMD is seeing straight lines appear wavy or distorted. This is called metamorphopsia, and it is a hallmark sign that something may be happening in the macula. Other early symptoms include a dark, blurry, or blank spot in the center of your vision, difficulty reading even with the right glasses, trouble recognizing faces, and colors that look less bright or vivid than usual.
These changes may appear gradually or quite suddenly. Either way, they should not be dismissed as normal aging. A prompt evaluation by a retina specialist is important whenever you notice a change in your central vision.
Some vision changes in wet AMD require immediate attention. Do not wait for a routine appointment if you experience any of the following.
- A sudden decrease or blurring of central vision
- Straight lines that appear wavy, bent, or distorted
- A new dark spot, shadow, or blank area in the center of your vision
- Any rapid or unexplained change in the quality of your eyesight
Wet AMD can progress quickly, and delaying evaluation by even a few days may result in additional and potentially permanent vision loss. Contact your retina specialist right away or seek emergency eye care if you experience any of these symptoms.
Wet AMD often affects one eye before the other. When only one eye is involved, the healthier eye tends to compensate, making it easy to miss early changes. Checking your vision one eye at a time, daily, using an Amsler grid (a simple chart with a grid of straight lines and a central dot) helps detect distortion that might otherwise go unnoticed until the condition has progressed further. Your care team can show you how to use this tool at home and what changes to look for.
How Wet AMD Is Diagnosed
Diagnosing wet AMD requires a combination of a thorough clinical examination and specialized retinal imaging. Our retina specialists use several advanced tools to evaluate the retina, confirm the diagnosis, and guide individualized treatment planning.
A comprehensive dilated eye exam is the foundation of wet AMD diagnosis. Eye drops are used to widen the pupil, allowing a clear and detailed view of the retina and macula. Your retina specialist will look for signs of abnormal blood vessels, fluid accumulation, bleeding, or early scarring beneath the retinal surface.
Optical coherence tomography, or OCT, is one of the most valuable diagnostic tools in retina care. It uses light waves to create precise cross-sectional images of the retinal layers, giving your specialist a detailed view of the retina's internal structure. OCT can reveal fluid beneath or within the retinal tissue, macula swelling, and changes in retinal thickness that may indicate active disease. The test is quick, painless, and non-invasive. It is also used routinely throughout treatment to monitor how well the retina is responding to therapy.
Fluorescein angiography is an imaging test that helps map abnormal blood vessels in and beneath the retina. A fluorescent dye called fluorescein is injected into a vein in the arm. As the dye travels through the blood vessels in the eye, a specialized camera captures a sequence of images that reveal exactly where and how blood vessels are leaking. This information helps your retina specialist determine the location and extent of the abnormal vessel growth and guides treatment decisions.
OCT angiography, or OCTA, is a newer imaging technique that visualizes blood flow in the retinal and choroidal layers without requiring a dye injection. It produces detailed maps of blood vessel patterns and can detect abnormal vessel growth in its early stages. While OCTA does not replace fluorescein angiography in all clinical situations, it is especially useful for ongoing monitoring and for patients who may not tolerate dye-based imaging as well.
Treatment Options for Wet AMD
Treatment for wet AMD has advanced significantly over the past two decades. With modern therapies and consistent care, most patients can expect their condition to be stabilized and meaningful vision preserved.
Anti-VEGF injections are the primary and most effective treatment available for wet AMD. These medications work by blocking vascular endothelial growth factor, the protein that drives abnormal blood vessel growth and fluid leakage in the retina. By reducing VEGF activity, anti-VEGF treatments help shrink abnormal vessels, reduce fluid buildup, and slow further damage to the macula.
Anti-VEGF medications are delivered as intravitreal injections, meaning they are injected directly into the vitreous (the gel-like substance that fills the inside of the eye). According to the American Academy of Ophthalmology, anti-VEGF therapy can stabilize vision in roughly 90 percent of patients and improve vision in approximately one in three patients. Outcomes depend on how early treatment begins and how the individual eye responds over time.
Several anti-VEGF medications are currently approved for the treatment of wet AMD. Each has a different molecular structure, dosing schedule, and duration of effect. Your retina specialist will recommend the most appropriate option based on your individual clinical picture and overall health.
- Ranibizumab (Lucentis): One of the first anti-VEGF treatments approved for wet AMD, typically given monthly
- Aflibercept (Eylea): Widely used, with dosing typically every four to eight weeks after an initial loading phase
- High-dose aflibercept (Eylea HD): A higher-concentration formulation that may support extended dosing intervals in appropriate patients
- Faricimab (Vabysmo): A bispecific antibody targeting both VEGF and a second pathway called angiopoietin-2, allowing many patients to extend treatment intervals to every 12 to 16 weeks
- Brolucizumab (Beovu): Dosed every eight to twelve weeks in appropriate patients; carries a small risk of retinal vasculitis (inflammation of the retinal blood vessels) that your specialist will discuss with you
- Bevacizumab (Avastin): Originally developed for cancer treatment and used off-label in retina care, this medication has a long and well-established track record of effectiveness in AMD
Treatment decisions are always individualized. Your retina specialist will consider your retinal anatomy, treatment history, overall health, and practical needs when recommending the most suitable medication and dosing schedule.
The Susvimo port delivery system is an option for certain patients who respond well to ranibizumab but would benefit from fewer office visits. A small, refillable implant is surgically placed in the wall of the eye, where it continuously releases medication into the vitreous over an extended period. Most patients require refills only about twice per year. A retina specialist can evaluate whether this approach is a good fit for your situation.
While anti-VEGF injections are the cornerstone of wet AMD care, other treatments may be used in specific circumstances. Photodynamic therapy (PDT) involves injecting a light-activated medication into the bloodstream, which is then activated by a specialized laser directed at the abnormal blood vessels. Traditional laser photocoagulation uses thermal energy to seal leaking vessels directly. Both are used less frequently today than in the past but may still be appropriate in certain clinical scenarios or alongside anti-VEGF therapy when needed.
What to Expect During Treatment
Starting treatment for wet AMD can feel overwhelming, but most patients find the process far more manageable than they expected. Here is what a typical course of care looks like.
Intravitreal injections are performed in a retina specialist's office, not in a hospital operating room. The eye is numbed with anesthetic drops or a small amount of numbing medicine, and the surface of the eye is carefully cleaned with an antiseptic solution to reduce the risk of infection. The injection itself takes only a few seconds.
Most patients feel a sensation of pressure during the injection rather than sharp pain. Mild redness, temporary blurred vision, and a slight gritty feeling afterward are common and typically resolve within a day or two. If you notice increasing pain, significant vision worsening, or any signs of infection after a procedure, contact your retina specialist promptly.
Most treatment plans begin with a loading phase of monthly injections, typically for the first two to three months. After this initial period, your retina specialist will use OCT imaging and clinical evaluations to assess your retina's response and determine whether injection intervals can be safely extended.
Some patients are eventually able to go several months between treatments. Others need more frequent injections to keep the condition stable. Skipping or delaying scheduled appointments can allow fluid to return and cause additional vision loss. Staying consistent with your care schedule is one of the most important things you can do to protect your vision over the long term.
Wet AMD is a chronic condition that requires long-term management. With consistent treatment, many patients are able to maintain useful central vision for years. The amount of vision that can be preserved depends in large part on how much damage occurred before treatment began. Vision lost to scarring before treatment starts typically cannot be recovered, which is why early detection and prompt care matter so much.
The goal of treatment is to control disease activity, prevent additional damage, and preserve as much functional vision as possible. Your retina specialist will work with you to develop a plan that balances effective treatment with the practical realities of your daily life.
Living with Wet Macular Degeneration
Managing wet AMD goes beyond regular clinic visits and injections. There are meaningful steps you can take at home to monitor your condition and support your overall eye health between appointments.
An Amsler grid is a simple self-monitoring tool consisting of a grid of straight lines with a central dot. Checking the grid daily, one eye at a time, can help you detect new distortion, wavy lines, or blank spots in your central vision. Any new or worsening changes should be reported to your retina specialist promptly, as they may indicate that the disease has become more active and requires treatment. Your care team can provide a printed grid and walk you through how to use it correctly at home.
Even with treatment, some patients experience lasting changes to central vision. Low vision specialists can recommend practical tools and strategies to help maintain independence and daily function. Magnifying lenses, large-print materials, high-contrast display settings on phones and computers, screen-reading software, and audiobooks are all commonly used resources. Adjusting task lighting and reducing glare in your home can also make reading and other close activities more manageable.
Certain lifestyle habits may support eye health and help slow AMD progression over time. Quitting smoking, if applicable, is one of the most impactful changes you can make. A diet rich in leafy green vegetables, colorful fruits, and fish containing omega-3 fatty acids may also be beneficial. Staying physically active, maintaining a healthy weight, managing blood pressure and cholesterol, and wearing UV-protective sunglasses all contribute to overall eye and vascular health.
The Age-Related Eye Disease Study 2 (AREDS2), conducted by the National Eye Institute, found that a specific combination of vitamins and minerals can reduce the risk of AMD progression in certain patients. Ask your retina specialist whether AREDS2 supplements are appropriate for your specific AMD stage and type before starting them on your own.
Frequently Asked Questions
Patients newly diagnosed with wet AMD often have important questions about what to expect. Here are answers to some of the most common concerns we hear in our practice.
While there is currently no cure for wet AMD, modern anti-VEGF therapy can control the disease effectively in most patients who receive consistent care. The key distinction is that treatment manages the condition rather than eliminating it. Stopping treatment or missing appointments significantly increases the risk of fluid returning and vision declining further. With ongoing care, many patients maintain stable vision for years, and the sooner treatment begins, the more vision can typically be preserved.
Wet AMD affects central vision, not peripheral (side) vision. Even in more advanced cases, most patients retain useful peripheral vision that supports mobility and independence. With today's anti-VEGF treatments, the risk of severe central vision loss is considerably lower than it was in prior decades before these therapies were available. That said, outcomes vary between individuals, and no treatment can guarantee a specific result. Your retina specialist will give you a clear and realistic picture of what to expect based on your unique situation.
Most patients require ongoing injections for many years, and many continue treatment indefinitely. Over time, your retina specialist will work to identify the longest interval that safely keeps your retina stable, which may reduce the number of visits needed per year. Stopping treatment without medical guidance puts you at real risk of disease reactivation and vision loss. Treatment plans are always adjusted based on how your individual eye responds, with the goal of using the minimum effective treatment frequency.
There is no guaranteed way to prevent dry AMD from progressing to the wet form. However, avoiding smoking, following a heart-healthy diet, managing blood pressure and cholesterol, and taking AREDS2 supplements when recommended can all play a protective role. Just as importantly, monitoring your vision daily with an Amsler grid allows you to detect early conversion and seek treatment immediately, which significantly improves outcomes compared to waiting until symptoms become obvious.
Yes, and this is one of the most active areas of progress in retina medicine. Faricimab (Vabysmo) and high-dose aflibercept (Eylea HD) have allowed many patients to extend treatment intervals to every 12 to 16 weeks or longer. The Susvimo port delivery system provides continuous medication release with only about two refills per year for qualifying patients. Researchers are also investigating gene therapy approaches designed to enable the eye to produce its own protective proteins long term, potentially reducing treatment burden significantly. Your retina specialist can discuss which extended-interval options may be appropriate for you.
Do not wait for your next scheduled visit. Sudden changes in central vision, new distortion, or a new dark spot should be treated as a potential emergency. Contact your retina specialist's office right away and explain that you are experiencing a sudden visual change. If you cannot reach your provider promptly, seek emergency eye care. Acting quickly gives you the best possible chance of limiting additional and permanent damage to your vision.
Visit New England Retina Associates
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons are dedicated to providing expert, compassionate care for patients living with wet AMD and other serious retinal conditions throughout Connecticut. We combine advanced diagnostic imaging, the latest approved therapies, and active involvement in clinical research to deliver individualized care based on the most current evidence available. If you have been diagnosed with wet AMD, have concerns about your risk, or have been referred by your eye care provider, we welcome you to schedule a consultation at any of our four convenient office locations.
30 Years of Care & Commitment
